黑色素瘤BRAF抑制剂耐药机制的研究进展

Research progress in the mechanism of BRAF inhibitor resistance in melanoma

黑色素瘤是一种源于黑色素细胞的恶性肿瘤,临床上约50%的黑色素瘤患者发生了BRAF突变。BRAF抑制剂能够作用于突变的BRAF位点,从而迅速对肿瘤细胞发挥增殖抑制和促进凋亡作用,但此后迅速发生的耐药事件严重制约了该类药物的连续使用,所以对于BRAF抑制剂耐药机制的探究非常重要。本文介绍了近年来有关黑色素瘤BRAF抑制剂耐药的相关研究进展,以期为后续的相关研究和临床应用提供一定的参考。

Melanoma is a malignant tumor of melanocyte origin,and BRAF mutations occur in about 50%of melanoma patients clinically.BRAF inhibitors can target mutated BRAF sites,thus rapidly inhibiting the proliferation and promoting apoptosis of tumor cells.However,the subsequent rapid occurrence of drug resistance events seriously restricted the continuous use of such drugs,so it is of great importance to explore the mechanism of BRAF inhibitors resistance.This paper introduces the research progress of BRAF inhibitor resistance in melanoma in recent years,in order to provide some references for the follow-up research and clinical application.